Glycosphingolipid Expression in Cerebrospinal Fluid of Infants with Neurological Abnormalities: Report of Three Cases by Maja Tomasović
Coll. Antropol. 32 (2008) Suppl. 1: 189–193
Case report
Glycosphingolipid Expression in Cerebrospinal
Fluid of Infants with Neurological Abnormalities:
Report of Three Cases
Maja Tomasovi}1, Biserka Re{i}1, Nada Ivelja2, Radenka Kuzmani}-[amija1, Jasminka Re{i}3,
Dragana Gabri} Panduri}4 Jo{ko Bo`i}5 and Anita Markoti}3
1 Department of Pediatrics, University Hospital »Split«, Split, Croatia
2 Department of Clinical Laboratory Diagnostics, University Hospital »Split«, Split, Croatia
3 Department of Medical Chemistry and Biochemistry, School of Medicine, University of Split, Split, Croatia
4 Department of Oral Surgery, School of Dental Medicine, University of Zagreb, Zagreb, Croatia
5 School of Medicine, University of Split, Split, Croatia
A B S T R A C T
The aim of this study was to analyse glycosphingolipid expression in cerebrospinal fluid (CSF) from one idiopathic
West syndrome (IWS) infant, one with Reye like syndrome, and one with congenital hydrocephalus, in comparison to
control group (n=7) using highly sensitive thin-layer chromatography-immunostaining methods. Gangliotetraose-se-
ries gangliosides (acidic glycosphingolipids) were not detected in CSF of infant with idiopathic West syndrome and in-
fant with congenital hydrocephalus. CSF of infant with IWS showed traces of neolacto-tetraose ganglioside fractions,
which were absent in all other CSF examined. In addition, lactosylceramide fraction, and one ceramide fraction were
highly expressed only in IWS CSF. These results confirmed previously described lack of gangliotetraose-series ganglio-
sides in IWS patient and for the first time is described increased expression of neolacto-series glycosphingolipids in IWS
patient. Since follow up until the age of five years showed almost normal IWS patient psychomotor development, the
discribed shift of glycosphingolipid expression may implicate on transient inhibition of specific glycosyl transferases in
the age of seven months.
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Introduction
A disturbance of brain maturation may be considered
to be a major contributing factor to the nuropathogenesis
of central nervous system. Although the basic mecha-
nism is still unknown, infantile spasms become appar-
ent during a phase of very active brain development
when neurites, dendrites, and synapses are maturing1,2.
A neurochemical understanding of the cell surface
events that accompany the development of a neuroblast
into a functionally mature neuron is important for deter-
mining the pathogeneses of age-dependent diseases. Be-
cause they are abundant in the outer surface of neuronal
plasma membrane, glycosphingolipids (GSLs) may play
an important role in these events3,4.
Izumi et al. found earlier low levels of cerebrospinal
fluid (CSF) gangliotetraose-series gangliosides in patients
with symptomatic or IWS5. In contrast to neutral GSLs
which don’t contain neuraminic acid, gangliosides are
acid class of GSLs. In addition to the gangliotetraose-se-
ries gangliosides analyses, for the first time we per-
formed determination of neolactoseries gangliosides and
neutral GSLs in an infant with IWS, one with Reye like
syndrome, and in one with congenital hydrocephalus, in
comparison to control group (n=7).
Materials and Methods
Subjects
Of the 3 infants, ages 1–12 months, with neurological
abnormalities one was diagnosed with idiopathic West
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syndrome (IWS), one with Reye like syndrome, and one
with congenital hydrocephalus. We analysed those sam-
ples in comparison to CSF samples obtained from 7 in-
fants admitted to our Clinic who required lumbar punc-
ture due to seizures, to exclude CNS infections or meta-
bolic disease. All of 7 control patients had febrile sei-
zures, ages 1–12 months, and all of them were without
psychomotor retardation or growth failure.
IWS patient had uneventful history: previous devel-
opment until the onset of seizures at six months of age
was normal, spasms were typical. EEG showed hypsar-
rhythmia. Cranial magnetic resonance imaging (MRI)
showed no demonstrable underlying cerebral lesion. Me-
tabolic findings were normal. CSF fluid was obtained be-
fore starting tetracoside therapy and showed no abnor-
malities (Table 1). Patient responded well on therapy and
was seizure free after seven days. At follow up until the
age of five years patient showed almost normal psycho-
motor development.
The patient with congenital hydrocephalus was ad-
mitted due to myoclonic seizures at age of 34 days. Pa-
tient was severely neurologically impaired and hypoto-
nic, and cranial ultrasound was performed6. Patient’s
head circumference was appropriate for age, but cranial
ultrasound showed extreme hydrocephalus (Figure 1 and
2). MRI revealed lissencephaly, hydrocephalus, callosal
agenesis, brainstem, cerebellar, and especially vermian
hypoplasia. Metabolic findings showed lactacidosis and
further investigation proved pyruvate dehydrogenase de-
ficiency. CSF was obtained before medication and sho-
wed increased lactate level (Table 1).
The Reye-like syndrome patient was previously healthy
child. Patient was admitted at age of 12 months due to le-
thargic state after urinary tract infection. Laboratory
findings showed abnormalities of hepatic function: mar-
ked elevation of aminotransferase and lactic dehydroge-
nase activity, hyperammoniaemia and prolongation of
prothrombin time. CSF was normal. Cranial ultrasound
showed no cerebral oedema. Screening for metabolic dis-
ease and further investigation showed ornithine trans-
carbamilase deficiency (OTC def), proved by DNA analy-
sis.
Additional seven patients had only febrile seizures
with normal developmental milestones and no neurologi-
cal disturbances. In all of the control patients (n=7) with
typical febrile seizures lumbar puncture was performed
to exclude CNS infection (Table 1).
In all patients (n=10) CSF specimens were obtained
before any therapy.
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TABLE 1
ROUTINE CEREBROSPINAL FLUID FINDINGS IN PATIENTS




Cell Count Proteins Glucose Lactate
WBC RBC g/L mmol/L mmol/L
IWS / 7 1/3 12/3 0.23 2.8 0.9
RLS / 12 1/3 0/3 0.37 1.3 –
CH / 1 6/3 15/3 0.83 3.4 4.0
control 1/5 12/3 12/3 0.45 3.1 –
control 2/6 18/3 0/3 0.43 4.8 –
control 3/1 20/3 208/3 0.72 2.0 1.5
control 4/8 3/3 15/3 0.52 2.8 –
control 5/7 7/3 19/3 0.39 3.1 1.3
control 6/10 2/3 6/3 0.29 3.2 1.0
control 7/12 1/3 15/3 0.33 4.4 –
ISW – idiopathic West syndrome, RLS – Reye like syndrome,
CH – congenital hydrocephalus.
Fig. 1. Cranial ultrasound finding in infant with
congenital hydrocephalus – frontal section.
Fig. 2. Cranial ultrasound finding in infant with
congenital hydrocephalus – parasagittal section.
Biochemical analyses of CSF glycosphingolipids
After routine analyses for clinical purpose we used
these specimens for analyses of glycosphingolipids. CSF
samples were stored at –80 °C until use. GSLs were ex-
tracted from defrosted samples with chloroform/metha-
nol (2/1, v/v), chloroform/methanol (1/1, v/v), and chloro-
form/methanol (1/2, v/v) (11-fold volumes of the CSF
volume) for 30 min with sonication7. The combined ex-
tracts were evaporated, resuspended in chloroform/ me-
thanol/water (30/60/8, by vol.), and gangliosides were
separated from neutral GSLs by anion exchange chroma-
tography on DEAE-Sepharose CL-6B (Pharmacia Fine
Chemicals, Freiburg, Germany). The ganglioside frac-
tion was incubated for 1 h at 37 °C in aqueous 1 N NaOH
to saponify phospholipids, followed by neutralization with
acetic acid and dialysis. After final column chromatogra-
phy purifications (Iatrobeads column 6RS-8060 for gan-
gliosides, Macherey-Nagel, Düren, Germany; silica gel 60
for neutral GSLs, Merck, Darmstadt, Germany) final
GSL fractions were adjusted to defined volumes of chlo-
roform/methanol (2/1) corresponding to half of the origi-
nal CSF volumes8.
Gangliosides were separated on silica gel 60 precoated
high-performance thin-layer chromatography plates (HP-
TLC-plates, size 10 x 10 cm, thickness 0.2 mm, Merck)
using chloroform/methanol/water (120/85/20, each by vol.)
with 2 mM CaCl2.
The HPTLC immunobinding assay using cholerage-
noid specifically detect GM1a ganglioside. To reveal the
presence of GD1a, GD1b, and GT1b, the silica gel plates
fixed with polyisobutylmethacrylate were incubated with
5 mU/mL V. cholerae neuraminidase (Behring Werke AG)
in 0.05 M NaAc, 9 mM CaCl2, pH5.5 (2 h, 37 °C) prior to
combined choleragenoid-immunostaining with the aim
to convert GD1a, GD1b, GT1b and GQ1b gangliosides
into GM1. Unspecific protein binding was blocked by a
15 min incubation of the plate with solution A (phos-
phate buffer saline, PBS supplemented with 1% bovine
serum albumin and 0.02% NaN3) and then for 2 h with
250 ng/mL choleragenoid (Sigma, Deisenhofen, Germa-
ny) diluted in solution A. Unbound choleragenoid was re-
moved by washing of plates five times with solution B
(0.05% Tween 21, 0.02% NaN3 in PBS) followed by goat
anti-choleragenoid (Calbiochem, Frankfurt, Germany)
and secondary rabbit anti-goat IgG antibody incubation
(both diluted 1:2000 in solution A). After 1 h incubation
with secondary antibody, the plates were washed again,
followed by twofold rinsing with glycine buffer (0.1 M
glycine, 1 mM ZnCl2, 1 mM MgCl2, pH 10.4), to remove
phosphate. Bound antibodies were visualized with 0.05%
(w/v) 5-bromo-4-chloro-3-indolylphosphate (Biomol, Ham-
burg, Germany) in glycine buffer. Each antibody analysis
was performed twice, with identical results.
The anti-nLc4Cer antibody recognizes the Galb1-4Glc-
NAc-residue and it shows some cross reactivity with
Galb1-4Glcb1-1Cer (lactosylceramide). Neuraminidase tre-
atment of neolacto-series gangliosides with (a2–3)- sub-
stituted sialic acid is necessary prior to immunostaining
with anti-nLcOse4Cer antibody, whereas (a2–6)-sialyla-
ted neolacto-type gangliosides can be detected without
enzyme treatment, because sialylation at the position 6
of the terminal galactose does not hinder recognition.
Fixed silica gel plates were incubated with 2.5 mU/mL V.
cholerae neuraminidase (Behring Werke AG) for 2 h at
37 °C in the buffer described above, followed by immuno-
staining with anti-nLc4Cer antibody. Secondary rabbit
anti-chicken IgG, affinity chromatography-purified and
labeled with alkaline phosphatase (0.6 mg/mL), was pur-
chased from Dianova and used in 1:2000 dilution. Bound
antibodies were visualized as described above.
Neutral GSLs were separated on silica gel 60 pre-
coated HPTLC-plates by solvent system chloroform/me-
thanol/water (120:70:12) containing 2 mM CaCl2 (ratios
are v/v/v) and visualized with orcinol.
The HPTLC immunostaing of neolacto-series neutral
GSLs was performed with anti-nLc4Cer antibody but
without neuraminidase pretreatment.
Results and Discussion
Using HPTL-immunostaining chromatohraphy, it was
possible to us to detect CSF GSLs in as little as 10–30 mL
of CSF5. Three or more fractions of gangliotetraose-se-
ries gangliosides, including GM1a, GD1a, GD1b, GT1b,
and GQ1b, were detected in all samples except in the
IWS CSF and hydrocephalus CSF (Figure 3).
No expression of gangliotetraose-series gangliosides in
IWS CSF in this study corresponds to the previous finding
by Izumi et al. who described low levels of CSF gan-
gliotetraose-series gangliosides both in symptomatic and
idiopathic West syndrome5. Due to more sensitive method,
we applied ten fold less amount of CSF at chromatograms
then Izumi et al5. In such small sample it was possible to
detect GSL fractions in the most CSF samples examined,
but not in IWS and congenital hydrocephalus CSF which
obviusly contained low levels of gangliotetraose-series
gangliosides. It could be suspected a problem in the
glycosphingolipid biosynthesis at the SIAT9 level, al-
though our patients’s normal development contrasts to
the severe disease present in children with SIAT9 defi-
ciency (Figure 4: deficient gangliosides GM1a, GD1a, GD-
1b, GT1b and GQ1b are marked in yellow colour). Ab-
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Fig. 3. HPTLC immunostain with cholera toxin B subunit after V.
cholerae neuraminidase treatment of ganglioside fractions corre-
sponding to 10 mL of the CSF of IWS (line 1), Reye’s syndrome (line
2) and congenital hydrocephalus (line 3). Control CSFs from neu-
rological healthy infants were applied at lines C1–C7. As a reference
was applied 10 ng of mouse brain gangliosides (lane S).
sence of gangliotetraose-series gangliosides in the CSF
fluid of the subject with congenital hydrocephalus is in the
discrepancy with previous finding by others9,10. The me-
thod used in this study is more sensitive and advanta-
geous for analysis of GSLs in CSF. Ten fold diluted sample
compared to previous assays allows optimal recognition
and interaction between GM1a glyco- antigen and cho-
leragenoid. Congenital hydrocephalus patient had in the
same time pyruvate dehydrogenase (PDH) deficiency. An-
aerobic glycolysis is slower due to the decreased regenera-
tion of NADH coenzyme in respiratory chain. The precursor
of sialic acid is glycolytic intermediate, phosphoenolpyru-
vate is. It is tempting to speculate that congenital hydro-
cephalus patient with PDH deficiency has lower content
of oligosialogangliosides due to decreased level of phos-
phoenolpyruvate and sialic acid.
Immunostaining with antibody against neolacto-se-
ries glycosphingolipids, after neuramindase treatment,
showed traces of neolacto-tetraose (IV3nLc4) ganglioside
in CWS CSF (Figure 5). All other samples examined were
negative (data not shown). Immunostaining of chroma-
togram of neutral glycosphingolipid extract, with anti-
body against neolacto-series glycosphingolipids, without
neuramindase treatment, revealed high level of one neu-
tral glycosphingolipid lactosyceramide (Figure 6, lane 1,
Lc2), and one ceramide fraction (Figure 6, lane 1, Cer).
All other samples examined were negative (data not
shown).
Using anti-neolacto-series GSL antibody, for the first
time we detected traces of neolacto-tetraose gangliosides
(IV3Neu5Ac-nLc4), high level of one fraction of lactosyl-
ceramide (Lc2), and one ceramide (Cer) fraction in IWS
CSF (Figure 4: IV3Neu5Ac-nLc4, Lc2 and Cer are mar-
ked in pink colour). Only scarce data were available
about neolacto-type gangliosides and neutral GSLs in the
brain. Vukeli} et al.11 described inhanced level of neola-
cto-tetraose ganglioside in both cerebral and anence-
phalic tissues compared to normal tissue. Mouse enzyme
Lc3 synthase (see overview of GSL synthesis in Figure 4)
is the key regulator of lacto-series GSL biosynthesis12. It
is broadly expressed during embryonic development,
whereas its expression postnatally is restricted to splenic
B lymphocytes, placenta, and cerebellar Purkinje cells.
Idiopathic epilepsies have been linked to genes con-
trolling ion channel function and receptor signalling on
neurons, whereas symptomatic epilepsies have been lin-
ked to genetic defects causing neurodegeneration and
disordered brain development13. Recently, Simpson et al.
described that defect in GM3 ganglioside synthase gene
underlied a severe early-onset symptomatic epilepsy syn-
drome14. Mice lacking correct GD3, GM2, and GD2 syn-
thase genes suffer seizures and they are unable to extend
Lc2 through GM2, GD3, and GD2 pathway to crucial
complex brain gangliosides13. Our finding fits in that re-
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Fig. 4. A schematic overview of GSL biosynthesis. GlcCer, Lc2, Lc3
and nLc4 are neutral GSLs synthesized by step-wise addition of su-
gar residues by specific glycosyl trasferases. All other molecules shown,
except ceramide (Cer), are gangliosides synthesized by addition of
sugar residues by distinct glycosyl transferases including sialyltran-
sferases. Mutations of glycosyl transferase genes encoding Galgt1,
Siat8a and Siat9 cause seizures in affected individuals13,14.
Fig. 5. HPTLC immunostain of neolacto-series gangliosides in 18
mL of the ISF of IWS (line 1). As a reference were applied 250 ng of
mouse brain gangliosides (lane S1) and 2 mg of human granulo-
cytes gangliosides (lane S2).
Fig. 6. HPTLC immunostain of neolacto-series neutral GSLs. Neu-
tral GSL amount corresponding to 30 mL of IWS CSF (line 1), was
chromatographed with 2 mg of mouse brain neutral GSLs (lane S1)
and 5 mg of human granulocytes neutral GSLs (lane S2). Orcinol
stain of neutral GSL refrerences applied in double amount is shown
at lines SO,1 and SO,2.
cent observation. The block of complex ganglioside syn-
thesis obviously caused accumulation of gangliosides pre-
cursors and increased built in of Lc2 in neolacto-series
GSLs instead in GM3 and consequently in complex brain
gangliosides (see overview of GSL synthesis in Figure 4).
Follow up until the age of five years showed almost nor-
mal IWS patient psychomotor development. Therefore,
the discribed shift of glycosphingolipid expression may
implicate on transient inhibition of specific glycosyl
transferases in the age of seven months. The discovery
by Simpson et al. that a human epilepsy syndrome is
caused by a defect in ganglioside synthesis was the begin-
ning of this important story14. This case report is just one
contribution to confirm it. Further unravelling of the
mechanism underlying seizures will not only increase
our understanding of epilepsies but also illuminate the
crucial functions of gangliosides in the brain.
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IZRA@AJ GLIKOSFINGOLIPIDA U CEREBROSPINALNOM LIKVORU DOJEN^ADI
S NEUROLO[KIM ODSTUPANJIMA: PRIKAZ TRIJU SLU^AJEVA
S A @ E T A K
Cilj ovog rada bila je analiza izra`aja glikosfingolipida u cerebrospinalnom likvoru tri dojen~eta s tri razli~ita neuro-
lo{ka odstupanja: idiopatskim Westovim sindromom (IWS), Reyevim sindromom i kongenitalnim hidrocefalusom, u
usporedbi s kontrolnom skupinom (n=7) upotrebom tankoslojne kromatografije visokog razlu~ivanja u kombinaciji s
imunobojenjem. U dojen~eta s idiopatskim Westovim sindromom i u dojen~eta s kongenitalnim hidrocefalusom nisu
dokazani gangliozidi gangliotetraozne serije (kiseli glikosfingolipidi). U likvoru dojen~eta s IWS gangliozidi neolakto-
tetraozne frakcije na|eni su u tragovima, a u svim ostalim uzorcima nisu dokazani. Pored toga samo u uzroku likvora
dojen~eta s IWS bila je izra`ena frakcija laktozilceramida i jedna ceramidna frakcija. Ovi rezultati potvr|uju ranije
opisani nedostatak gangliozida gangliotetraozne serije u pacijenata s IWS. Prvi put opisan je pove}an izra`aj glikosfin-
golipida neolakto-serije u pacijenata s IWS. Obzirom da je IWS pacijent pokazao normalan psihomotorni razvoj tijekom
pra}enja do pete godine `ivota, opisano skretanje izra`aja GSL ukazuje na mogu}u prolaznu inhibiciju specifi~nih gliko-
zil transferaza u dobi od sedam mjeseci.
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